CareDx Finalizes Naveris Acquisition, Expands into High-Growth Oncology
CDNA has more than doubled off its 52-week low of $10.96.
Summary
CareDx has completed its acquisition of Naveris, a strategic move that expands its presence into the high-growth specialty oncology market. This finalizes the deal that was initially announced on April 28th, which coincided with the company's strong first-quarter earnings report and raised guidance. The completion allows CareDx to integrate Naveris and further its strategic focus on diagnostics.
At the time of this announcement, CDNA was trading at $29.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $10.96 to $29.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.